Monopar Therapeutics

MNPR

Monopar Therapeutics

MNPR

Insider Sentiment (TTM):

Last Purchase:2025-12-26Last Sale:2025-12-18Shares Purchased (TTM):1,500Shares Sold (TTM):555,350

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:6,185,305Shares Outstanding:8,535,443Institutional Ownership Pct.:72.47%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Cash And Cash Equivalents At Carrying Value	53	53	62	128	40	40	46	6	6	8	7	6
Investments	82	85	79	16	14	15	14	-	1	1	0	3
Assets Current
Assets Current	135	138	140	144	54	55	60	6	7	9	7	9
Other Assets Current	0	0	0	0	0	1	0	0	0	0	0	0
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Assets	135	138	141	144	54	55	60	6	7	9	7	9
Accounts Payable And Accrued Liabilities Current	4	2	3	3	2	1	2	1	1	1	2	2
Liabilities Current
Liabilities Current	4	2	3	3	2	-	5	-	-	-	2	2
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	-	0	0
Liabilities	4	3	3	3	2	1	5	1	1	1	2	2
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity	131	135	138	142	52	54	55	5	6	7	6	7
Additional Paid In Capital Common Stock	229	229	227	226	133	132	131	70	70	69	66	65
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	-0	0	-0	0	0	-0	0
Retained Earnings Accumulated Deficit	-99	-93	-90	-84	-81	-78	-76	-65	-64	-62	-60	-58
Liabilities And Stockholders Equity	135	138	141	144	54	55	60	6	7	9	7	9
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	40	40	40	40	40	40	40	40	40	40	40	40
Common Stock Shares Issued	7	7	7	7	6	6	6	4	4	3	3	3
Shares Outstanding	7	7	7	7	6	6	6	4	4	3	3	3

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.48%	60.34%	88.00%	-	-	-	-	-	-	-	-	-
2025	9.73%	7.19%	20.31%	23.15%	176.85%	140.00%	-7.62%	-24.14%	-30.61%	3.92%	9.56%	10.48%
2024	-14.06%	2.67%	1.27%	8.14%	206.33%	666.06%	33.47%	45.32%	145.62%	17.30%	-2.64%	-9.75%
2023	-	-	-	-	-	-	-20.67%	-18.27%	-12.50%	-6.02%	-10.43%	38.03%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	33.56	56.04	51.35	56.10	33.94	-	11.47	-	-	-	4.17	4.32
Quick Ratio	33.56	56.04	51.35	56.10	33.94	-	11.47	-	-	-	4.17	4.32
Working Capital	130.75M	135.29M	137.73M	141.52M	52.16M	-	55.04M	-	-	-	5.58M	6.59M
Leverage & Debt
Debt to Equity	0.03	0.02	0.02	0.02	0.03	-	0.10	-	-	-	0.31	0.30
Interest Coverage TTM	-	-	-	-	-	-240.36	-103.84	-27.59	-20.47	-19.09	-20.58	-28.60
Debt Ratio	0.03	0.02	0.02	0.02	0.03	-	0.09	-	-	-	0.24	0.23
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Free Cash Flow Per Share TTM	-1.68	-1.17	-1.65	-0.73	-0.59	-1.49	-1.69	-1.69	-1.95	-2.27	-2.84	-2.70
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	3.10%	-9.57%	-11.99%	200.27%	142.95%	117.77%	85.50%	-31.73%	-28.26%	-27.49%	-20.10%	-7.92%
EPS Growth (1Y)	-15.54%	-25.97%	-54.99%	48.39%	21.61%	-0.39%	35.32%	-45.24%	-45.03%	-40.53%	-26.49%	-16.81%
Valuation Metrics
P/E TTM	-44.32	-31.21	-35.28	-29.93	-14.47	-15.35	-5.35	-3.66	-1.79	-1.43	-0.56	-0.92
P/B TTM	6.04	3.45	3.51	4.11	4.80	4.75	1.52	4.80	2.10	1.46	0.84	1.32
Market Cap	790.95M	467.66M	483.95M	581.80M	250.39M	254.41M	83.38M	23.73M	12.79M	10.88M	4.70M	8.75M
Enterprise Value	738.19M	415.11M	422.11M	454.13M	210.89M	214.70M	37.57M	17.71M	6.67M	3.07M	-2.57M	3.24M
Calculated Values
Free Cash Flow TTM	-14.37M	-10.01M	-12.20M	-5.17M	-4.15M	-10.41M	-6.40M	-5.95M	-6.82M	-7.24M	-7.86M	-7.61M
Net Debt	-52.76M	-52.54M	-61.83M	-127.68M	-39.50M	-39.71M	-45.82M	-6.02M	-6.12M	-7.81M	-7.27M	-5.52M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-26Purchase

Owner: Vu, Quan Anh

Title: Chief Financial Officer

Shares: 1,500

Price/Share: $69.95

Value: $104,925.00

Shares Owned: 1,500

Relationship: Officer

Ownership: Direct

2025-12-18Sale

Owner: Klausner, Arthur J

Title: -

Shares: 5,121

Price/Share: $67.58

Value: $346,077.18

Shares Owned: 8,762

Relationship: Director

Ownership: Direct

2025-09-24Sale

Owner: Tactic, Pharma Llc, Brown…

Title: Chief Executive Officer

Shares: 550,229

Price/Share: $63.61

Value: $35,000,066.69

Shares Owned: 272,026

Relationship: Other

Ownership: Direct

2025-07-14Sale

Owner: Robinson, Chandler

Title: Chief Executive Officer

Shares: 16,800

Price/Share: $40.00

Value: $672,000.00

Shares Owned: 73,472

Relationship: Director,Officer

Ownership: Direct

2025-07-14Sale

Owner: Tsuchimoto, Kim R

Title: -

Shares: 8,904

Price/Share: $40.00

Value: $356,160.00

Shares Owned: 11,486

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-26	Vu, Quan Anh	Officer	Chief Financial Officer	Direct	Purchase	1,500	69.95	$104,925.00	1,500	4
2025-12-18	Klausner, Arthur J	Director	-	Direct	Sale	5,121	67.58	$346,077.18	8,762	4
2025-09-24	Tactic, Pharma Llc, Brown…	Other	Chief Executive Officer	Direct	Sale	550,229	63.61	$35,000,066.69	272,026	4
2025-07-14	Robinson, Chandler	Director,Officer	Chief Executive Officer	Direct	Sale	16,800	40.00	$672,000.00	73,472	4
2025-07-14	Tsuchimoto, Kim R	Director	-	Direct	Sale	8,904	40.00	$356,160.00	11,486	4
2025-07-14	Starr, Christopher M	Director	-	Direct	Sale	16,800	40.00	$672,000.00	5,173	4
2025-04-02	Brown, Michael J, Robinso…	Director,Officer,TenPercentOwner,Other	Chief Executive Officer	Direct	Sale	33,334	35.00	$1,166,690.00	822,255	4
2024-10-28	Radhakrishnan, Karthik	Officer	Chief Financial Officer	Direct	Purchase	1,550	16.25	$25,187.50	1,550	4
2024-06-20	Cittadine, Andrew	Officer	Chief Operating Officer	Direct	Purchase	20,508	0.74	$15,175.92	186,132	4
2024-06-17	Cittadine, Andrew	Officer	Chief Operating Officer	Direct	Purchase	12,000	0.90	$10,800.00	153,624	4
2024-06-04	Cittadine, Andrew	Officer	Chief Operating Officer	Direct	Purchase	12,000	0.78	$9,360.00	117,624	4
2024-05-31	Cittadine, Andrew	Officer	Chief Operating Officer	Direct	Purchase	12,000	0.64	$7,680.00	93,624	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

72.47%

Inst. Shares: 6,185,305

Shares Outstanding: 8,535,443

2025-12-31

74.05%

Inst. Shares: 5,488,105

Shares Outstanding: 7,411,121

2025-09-30

60.86%

Inst. Shares: 4,335,787

Shares Outstanding: 7,123,849

2025-06-30

45.24%

Inst. Shares: 3,166,183

Shares Outstanding: 6,998,082

2025-03-31

41.19%

Inst. Shares: 2,877,799

Shares Outstanding: 6,987,381

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	6,185,305	8,535,443	72.47%
2025-12-31	5,488,105	7,411,121	74.05%
2025-09-30	4,335,787	7,123,849	60.86%
2025-06-30	3,166,183	6,998,082	45.24%
2025-03-31	2,877,799	6,987,381	41.19%
2024-12-31	2,578,295	3,790,202	68.03%
2024-09-30	15,707	3,520,398	0.45%
2024-06-30	399,341	3,502,927	11.40%
2024-03-31	339,342	3,195,963	10.62%
2023-12-31	168,124	2,764,790	6.08%
2023-09-30	288,243	2,823,680	10.21%
2023-06-30	192,440	2,684,006	7.17%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Monopar Therapeutics (MNPR) — SEC Financial Statements & Analysis

Monopar Therapeutics (MNPR) is a pharmaceutical preparations company, incorporated in DE. Monopar Therapeutics trades on Nasdaq as: MNPR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Monopar Therapeutics reported a Debt-to-Equity ratio of 0.03x, a Price-to-Book (P/B) ratio of 6.04x (TTM), at a market cap of $790.95M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.03x
P/B TTM: 6.04x
Market Cap: $790.95M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Monopar Therapeutics in?

Monopar Therapeutics (MNPR) operates in the Pharmaceutical Preparations industry.

What is MNPR's market cap?

Monopar Therapeutics (MNPR) has a market capitalization of $790.95M as of 2026-06-30.

What exchange does MNPR trade on?

Monopar Therapeutics (MNPR) trades on the Nasdaq.

Where is Monopar Therapeutics incorporated?

Monopar Therapeutics is incorporated in DE.